TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01121224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Patients receive one or more bare metal stents in the saphenous vein graft target lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent
Description: Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded clopidogrel
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine (open-label)
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine (open-label)
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
Study: NCT03598075

Intervention type: OTHER
Group type: OTHER
Intervention: Amylin (Pramlintide)
Description: Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .

Intervention type: OTHER
Group type: OTHER
Intervention: CGRP
Description: CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
Study: NCT02871869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini Tablets
Description: 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini Tablets
Description: 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/㎡,one day before CHOP protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/㎡,one day before CHOP protocol
Study: NCT04270331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PADS protocol
Description: Assessment and management per PADS protocol
Study: NCT00744068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Care Telephone Support
Description: Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Care Telephone Support
Description: Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
Study: NCT01574235

Intervention type: BIOLOGICAL
Intervention: Nivestim®
Study: NCT02825875

Intervention type: DRUG
Intervention: 18F DCFPyL- Radiopharmaceutica
Study: NCT02042573

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS

Intervention type: DRUG
Group type: OTHER
Intervention: SSRI (SEROPLEX ou ZOLOFT)

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic samples

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic samples

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic samples
Study: NCT05069376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Stent of 5-16 or 5-18
Description: Boston Scientific Polaris™ Ultra Ureteral Stent
Study: NCT05959460

Intervention type: OTHER
Intervention: Deuterium dose-to-mother method for assessing breastfeeding
Description: Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
Study: NCT02754531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: USG
Description: USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cole Formula
Description: Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
Study: NCT03158194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for anxiety-related asthma
Description: The specific assignments in the intervention will be based on individual behavior analysis for each participant.
Study: NCT01450761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study: NCT01220739

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Laser Therapy
Description: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Laser Therapy
Description: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
Study: NCT03741504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations (MOPs)
Description: three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
Study: NCT03859271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Description: Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
Study: NCT00268840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
Study: NCT05193162

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention
Study: NCT02911675

Intervention type: DEVICE
Intervention: EVD/IVC and the IPM/Camino
Description: This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.

Intervention type: DEVICE
Intervention: EVD/IVC and the IPM/Camino
Description: This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
Study: NCT01470391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-Blockade with Ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: US-guided Femoral Nerve Block with Ropivacaine
Study: NCT01153581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Description: Ganirelix acetate: .25 ml/day by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-Oestradiol
Description: 17 beta estradiol: 0.2 mg/day (patches)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: progesterone, 200 mg day-1 oral
Study: NCT05193162

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention

Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention
Study: NCT00181766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strattera (atomoxetine)
Description: Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
Study: NCT01664182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT03765294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet for oral use
Study: NCT01556204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
Study: NCT02456324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICS-AF Device
Description: This is a specialized closure system for anorectal fistulas that is sphincter sparing
Study: NCT01664182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT02144857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: 45 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine 2.5-3 mg/kgr
Study: NCT05069376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral Stent of 5-22 or 5-24
Description: Boston Scientific Polaris™ Ultra Ureteral Stent
Study: NCT00515879

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions aim to help participants become more comfortable with social situations.
Study: NCT02144857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: 30mg
Study: NCT04496856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and Collagen supplementation
Description: Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and Collagen supplementation
Description: Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
Study: NCT02919046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study: NCT02036125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Subjects will receive a blind injection of 40 mg of methylprednisolone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Subjects will receive a blind injection of 40 mg of methylprednisolone.
Study: NCT02456324

Intervention type: DEVICE
Group type: OTHER
Intervention: Historical Controls Treated with Commercially Available Fistula Plugs
Description: These are patients previously treated with commercially available fistula plugs.
Study: NCT00515879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage as active pill
Study: NCT03836768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Description: DTRMWXHS-12 capsules: 150 mg, 300 mg
Study: NCT01880658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
Study: NCT04293185

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: bb1111
Description: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT03728543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection
Study: NCT03959059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality technology
Description: combine image with real body
Study: NCT03168412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Study: NCT03856502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone
Description: Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12,5 mg of 0,5 % of levobupivacaine
Description: Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12,5 mg of 0,5 % of levobupivacaine
Description: Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
Study: NCT03168412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study: NCT00508326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 150 mg/m\^2 HAI once every 4 weeks
Study: NCT03189394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIDE
Description: A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePRIDE
Description: A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Men's Health
Description: A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.